JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Research on Anti-lipogenic Effect of Sobuncheong-eum on Experimental Cellular Model of Non-alcoholic Fatty Liver Disease
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Herbal Formula Science
  • Volume 24, Issue 2,  2016, pp.100-107
  • Publisher : The Korean Journal of Oriental Medical Prescription
  • DOI : 10.14374/HFS.2016.24.2.100
 Title & Authors
Research on Anti-lipogenic Effect of Sobuncheong-eum on Experimental Cellular Model of Non-alcoholic Fatty Liver Disease
Lee, Hye-in; Kim, Ji-su; Kim, Cheon-jung; Kim, Ha-na; Yang, Tae-jun; Jeong, Sang-jun; Choi, Chang-Won;
  PDF(new window)
 Abstract
Objectives : The purpose of this study is to evaluate the anti-lipogenic effect of Sobuncheong-eum on non-alcoholic fatty liver disease in free fatty acid induced cellular model. Methods : HepG2 cells were treated with palmitate for 24h to overload intracellular triglyceride (TG) content in the presence or absence of Sobuncheong-eum extract. After palmitate treatment, Intracellular TG content was measured with TG assay kit. Several lipogenesis related markers, including AMP-activated protein kinase (AMPK), sterol regulatory element-binding transcription factor-1c (SREBP-1c), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS), were assessed using Western-blot analyses and RT-PCR. Results : Palmitate markedly increased intracellular TG in HepG2 cells, and which were alleviated by coadministered Sobuncheong-eum extract. Sobuncheong-eum extract activated AMPK, which plays a key role in reducing hepatic lipid accumulation, and reduced lipogenic fators, SREBP-1c, ACC, and FAS. Conclusions : Taken together, it is conceivable that Sobuncheong-eum has an potential to alleviate steatosis, and which may be mediated by activating AMPK at least in part.
 Keywords
Sobuncheong-eum;non-alcoholic fatty liver disease;AMPK;HepG2 cell;
 Language
Korean
 Cited by
 References
1.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23. crossref(new window)

2.
Angulo P. Nonalcoholic fatty liver disease. Revista de gastroenterologia de Mexico. 2005;70 Suppl 3:52-6.

3.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9. crossref(new window)

4.
Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clinics in liver disease. 2009;13(4):511-31. crossref(new window)

5.
Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. Journal of clinical and translational hepatology. 2015;3(3):230-8. crossref(new window)

6.
Yeon JE. Nonalcoholic Fatty Disease : pathogenesis and treatment. J of KAHP. 2006;4:132-9.

7.
Lee NG. Hyeontojuseog Gyeongagjeonseo. Seoul: Bubin Publishers Co, 2007:1021.

8.
Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. The Journal of physiology. 2006;574(Pt 1):41-53. crossref(new window)

9.
Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes & development. 2000;14(22):2819-30. crossref(new window)

10.
Pettinelli P, Obregon AM, Videla LA. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutricion hospitalaria. 2011;26(3):441-50.

11.
Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Molecular biology reports. 2012;39(10):9715-22. crossref(new window)

12.
Traditional Chinese Association. Guidelines for Diagnosis and Treatment of Common Internal Diseases in Chinese Medicine Diseases of Modern Medicine. Beijing: China Traditional China Medicine Publisher, 2008:153.

13.
Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiological reviews. 2009;89(3):1025-78. crossref(new window)

14.
Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta physiologica. 2009;196(1):81-98. crossref(new window)

15.
Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A, La Mura V, Garcia-Pagan JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. Journal of hepatology. 2011;55(5):1095-102. crossref(new window)

16.
Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K, et al. Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. The Journal of nutritional biochemistry. 2013;24(5):796-802. crossref(new window)